Literature DB >> 12653850

Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis.

K Shigehara1, N Shijubo, M Ohmichi, K Kamiguchi, R Takahashi, S Morita-Ichimura, T Ohchi, T Tatsuno, Y Hiraga, S Abe, N Sato.   

Abstract

In sarcoidosis, a T helper 1 (Th1) response is an essential event and the up-regulation of interleukin-12 (IL-12) has been detected in affected disease sites. In order to investigate the clinical usefulness of circulating IL-12, we measured the serum concentrations of IL-12 by ELISA and performed immunohistochemistry using specific MoAbs for IL-12 in the lungs and scalene lymph nodes of patients with sarcoidosis. The serum concentration of IL-12 p40 was detectable in all 45 patients with pulmonary sarcoidosis and 18 normal controls, whereas that of IL-12 p70 was undetectable. The serum concentrations of IL-12 p40 in pulmonary sarcoidosis were significantly higher than those of the normal controls, especially in cases with abnormal intrathoracic findings detected by chest roentogenogram. The serum concentrations of interferon-gamma (IFN-gamma) also increased compared with those of normal controls and there was a significant positive correlation between the serum concentrations of IL-12 p40 and IFN-gamma. Furthermore, serum angiotensin-converting enzyme (ACE) and lysozyme, which are known to be useful markers for disease activity in sarcoidosis, correlated well with the serum concentrations of IL-12 p40. The positive 67Ga scan group (for lung field) had significantly elevated serum IL-12 p40 levels compared with those of the negative group. No bioactivity of IL-12 p70 was detected in three sarcoid cases sera by using the IL-12 responsive cell line. Finally, the immunohistochemical approach revealed that IL-12 p40 was expressed in the epithelioid cells and macrophages of sarcoid lungs and lymph nodes. We concluded that the production of IL-12 p40 was far greater in the sera and we have demonstrated this to be a useful clinical marker for disease activity and the Th1 response in pulmonary sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653850      PMCID: PMC1808667          DOI: 10.1046/j.1365-2249.2003.02105.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Reduced T helper 1 responses in IL-12 p40 transgenic mice.

Authors:  T Yoshimoto; C R Wang; T Yoneto; S Waki; S Sunaga; Y Komagata; M Mitsuyama; J Miyazaki; H Nariuchi
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

2.  Effective stimulation for IL-12 p35 mRNA accumulation and bioactive IL-12 production of antigen-presenting cells interacted with Th cells.

Authors:  H Yamane; T Kato; H Nariuchi
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

3.  Characterization of mouse interleukin-12 p40 homodimer binding to the interleukin-12 receptor subunits.

Authors:  X Wang; V L Wilkinson; F J Podlaski; C Wu; A S Stern; D H Presky; J Magram
Journal:  Eur J Immunol       Date:  1999-06       Impact factor: 5.532

Review 4.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

5.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

6.  In vivo production and function of IL-12 p40 homodimers.

Authors:  F P Heinzel; A M Hujer; F N Ahmed; R M Rerko
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

7.  Serum interleukin 12 concentration in juvenile chronic arthritis.

Authors:  M Gattorno; P Picco; S Vignola; F Stalla; A Buoncompagni; V Pistoia
Journal:  Ann Rheum Dis       Date:  1998-07       Impact factor: 19.103

8.  IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma.

Authors:  T Hoshino; R T Winkler-Pickett; A T Mason; J R Ortaldo; H A Young
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

Review 9.  Sarcoidosis: immunopathogenetic concepts and their clinical application.

Authors:  J Müller-Quernheim
Journal:  Eur Respir J       Date:  1998-09       Impact factor: 16.671

10.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.

Authors:  M Cella; D Scheidegger; K Palmer-Lehmann; P Lane; A Lanzavecchia; G Alber
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  14 in total

1.  Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis.

Authors:  M Veltkamp; P A H M Wijnen; C H M van Moorsel; G T Rijkers; H J T Ruven; M Heron; O Bekers; A M E Claessen; M Drent; J M M van den Bosch; J C Grutters
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

Review 2.  Cytokine modulators in the treatment of sarcoidosis.

Authors:  E Bargagli; C Olivieri; P Rottoli
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 3.  Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease.

Authors:  Lin Sun; Chang He; Lekha Nair; Justine Yeung; Charles E Egwuagu
Journal:  Cytokine       Date:  2015-03-18       Impact factor: 3.861

Review 4.  The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.

Authors:  Julie H Wu; Sotonye Imadojemu; Avrom S Caplan
Journal:  Am J Clin Dermatol       Date:  2022-05-18       Impact factor: 6.233

5.  Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease.

Authors:  Karen C Patterson; Beverly S Franek; Joachim Müller-Quernheim; Anne I Sperling; Nadera J Sweiss; Timothy B Niewold
Journal:  Cytokine       Date:  2013-02-04       Impact factor: 3.861

6.  The anergic state in sarcoidosis is associated with diminished dendritic cell function.

Authors:  Sneha Mathew; Kristy L Bauer; Arne Fischoeder; Nina Bhardwaj; Stephen J Oliver
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins.

Authors:  Dario Venetz; Danil Koovely; Bruce Weder; Dario Neri
Journal:  J Biol Chem       Date:  2016-07-08       Impact factor: 5.157

8.  Differential inflammatory microRNA and cytokine expression in pulmonary sarcoidosis.

Authors:  Agnieszka Jazwa; Lukasz Kasper; Maciej Bak; Mateusz Sobczak; Krzysztof Szade; Alicja Jozkowicz; Krzysztof Sladek; Jozef Dulak
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-11-01       Impact factor: 4.291

Review 9.  Interleukin-12 family cytokines and sarcoidosis.

Authors:  Sabine Ringkowski; Paul S Thomas; Cristan Herbert
Journal:  Front Pharmacol       Date:  2014-10-27       Impact factor: 5.810

10.  The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.

Authors:  Ozlem Sahin; Alireza Ziaei; Eda Karaismailoğlu; Nusret Taheri
Journal:  BMC Ophthalmol       Date:  2016-02-16       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.